Related Experiment Video
Updated: Feb 17, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
18.0K
Incidental venous thromboembolism: is anticoagulation indicated?
Marcello Di Nisio1,2, Marc Carrier3
1Department of Medicine and Ageing Sciences, G. D'Annunzio University, Chieti, Italy.
Hematology. American Society of Hematology. Education Program
|December 10, 2017
Summary
Cancer patients with incidentally detected venous thromboembolism (VTE) have similar outcomes to symptomatic VTE. Anticoagulation is recommended for 3-6 months for most incidental VTE, with individualized treatment decisions thereafter.
Area of Science:
- Oncology
- Hematology
- Vascular Medicine
Background:
- Patients with cancer face a high risk of venous thromboembolism (VTE).
- Approximately 50% of VTE events in cancer patients are incidentally discovered.
- Incidental VTE carries a prognosis similar to symptomatic VTE, with high recurrence rates.
Purpose of the Study:
- To review the management of incidental VTE in cancer patients.
- To provide guidance on anticoagulation duration and patient-specific considerations.
Main Methods:
- Literature review and synthesis of current guidelines.
- Analysis of prognostic factors and treatment outcomes for incidental VTE in cancer.
Main Results:
- Incidental proximal deep vein thrombosis and pulmonary embolism involving multiple or more proximal arteries warrant 3-6 months of low-molecular-weight heparin.
- Extended anticoagulation beyond 6 months requires case-by-case evaluation of bleeding risk, VTE recurrence risk, and patient preference.
- The significance of single incidental subsegmental pulmonary embolism without deep vein thrombosis is unclear, suggesting watchful waiting or shorter anticoagulation.
- Anticoagulation may benefit cancer patients with incidental distal deep vein thrombosis or splanchnic vein thrombosis.
Conclusions:
- Standard anticoagulation protocols are generally applicable to incidental VTE in cancer patients.
- Individualized risk-benefit assessments are crucial for treatment decisions, particularly for extended anticoagulation.
- Further research is needed to clarify management strategies for specific VTE presentations in this population.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
383
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
383
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
355
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
355
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
01:30Venous Thrombosis I: Introduction
504
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
504
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
01:30Venous Thrombosis IV: Nursing Management
278
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
278